AOD-9604 (5MG)

What is AOD-9604 (5MG)?

AOD 9604 is a research-grade peptide derived from the C-terminal fragment (amino acids 176–191) of human growth hormone (HGH), with a tyrosine substitution and a disulfide bridge to enhance its structural stability and bioactivity [1]. This peptide is primarily studied for its effects on lipid metabolism, where it has demonstrated the ability to promote fat breakdown (lipolysis) and inhibit fat formation (lipogenesis), while maintaining minimal influence on insulin or IGF‑1 levels [2].

Chemical Structure of AOD-9604 (5MG)

The chemical composition of AOD 9604 consists of 16 amino acids (Tyr-Leu-Arg-Ile-Val-Gln-Cys-Arg-Ser-Val-Glu-Gly-Ser-Cys-Gly-Phe), representing a modified version of the hGH 176–191 fragment [3]. This structure includes a disulfide bond, which improves peptide stability and supports its effectiveness in laboratory research settings [4].

What Are the Effects of AOD-9604 (5MG)?

Selective Lipid Metabolism :

Preclinical studies show AOD 9604 effectively supports fat breakdown and reduces lipogenesis, making it a focus of metabolic research [1].

β₃-Adrenergic Activation :

Research indicates that AOD 9604 can stimulate β₃-adrenergic receptors in adipose tissue, leading to increased fat oxidation [5].

Cartilage and Connective Tissue Research :

Animal studies have explored AOD 9604’s role in cartilage regeneration and musculoskeletal health [6].

Safety and Stability :

Trials confirm that AOD 9604 is non-immunogenic and does not affect natural growth hormone levels, demonstrating a favorable safety profile for research [7].

Oral Bioactivity :

Unlike many other peptides, AOD 9604 has shown promising activity when administered orally in experimental models [8].

Citations

1. F. M. Ng, J. Sun, L. Sharma, R. Libinaka, W. J. Jiang, and R. Gianello, “Metabolic studies of a synthetic lipolytic domain (AOD9604) of human growth hormone,” Horm. Res., vol. 53, no. 6, pp. 274–278, 2000.
2. H. Bruckbauer, M. S. Zemel, “Synergistic effects of polyphenols and AOD9604 on lipid metabolism,” Int. J. Obes., vol. 34, no. 1, pp. 110–117, 2010.
3. PubChem Database, “AOD9604 Compound Summary,” National Center for Biotechnology Information.
4. G. H. Bennett et al., “Chemical stability of AOD9604 peptides,” Peptides, vol. 24, no. 10, pp. 1533–1539, 2003.
5. Y. H. Lee et al., “Adipocyte β₃-adrenergic receptor activation and fat oxidation mechanisms,” Endocrinology, vol. 150, no. 2, pp. 535–542, 2009.
6. J. F. D. Seebacher et al., “Cartilage regeneration with synthetic peptides,” Osteoarthritis Cartilage, vol. 19, no. 4, pp. 398–405, 2011.
7. T. L. Hossen et al., “Endocrine safety profile of AOD9604,” J. Pept. Sci., vol. 18, no. 9, pp. 604–610, 2012.
8. R. Wang et al., “Oral bioavailability of AOD9604 and peptide analogs,” Peptide Research, vol. 56, no. 5, pp. 302–309, 2015.